Current disease status-First occurrence of the cancer - Page 5 of 59 Posts on Medivizor
Navigation Menu

Current disease status-First occurrence of the cancer Posts on Medivizor

Comparing outcome in robotic-assisted versus laparoscopic prostate surgery

Comparing outcome in robotic-assisted versus laparoscopic prostate surgery

Posted by on Mar 10, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the effectiveness of functional and oncological outcomes of robotic-assisted (RA) and laparoscopic (Lap) radical prostatectomy (RP; removal of the prostate) in localized and locally advanced prostate cancer (PCa). the study concluded that RARP was similarly effective and had better urinary and sexual outcomes...

Read More

Can intraoperative radiotherapy be used to treat early-stage breast cancer?

Can intraoperative radiotherapy be used to treat early-stage breast cancer?

Posted by on Mar 6, 2021 in Breast cancer | 0 comments

In a nutshell This article looked at 5-year outcomes of intraoperative radiation therapy (IORT) for breast cancer (BC). The authors found that IORT may have a higher rate of cancer return compared to whole-breast radiation therapy (WBRT). Some background BC is one of the most common forms of cancer found in women. Standard care for BC is usually a...

Read More

Evaluating the use of radiotherapy followed by chemotherapy before surgery for locally-advanced rectal cancer.

Evaluating the use of radiotherapy followed by chemotherapy before surgery for locally-advanced rectal cancer.

Posted by on Feb 14, 2021 in Colorectal cancer | 0 comments

In a nutshell This trial looked at the use of short-course radiotherapy (RT) followed by chemotherapy (CT) and delayed surgery to reduce distant metastases (tumor spread) in patients with locally advanced rectal cancer (LARC). The trial found that this treatment was more effective in controlling distant metastases when compared to standard...

Read More

Comparing outcomes in single-port versus multiport robotic radical prostate surgery

Comparing outcomes in single-port versus multiport robotic radical prostate surgery

Posted by on Feb 13, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the surgical outcomes of patients undergoing single-port extraperitoneal prostatectomy (SP-EPP) with conventional multiport transperitoneal robot-assisted radical prostatectomy (MP-RARP). The data showed that the SP-EPP approach was associated with a shorter length of hospital stay as well as a reduction in pain...

Read More

Is chemotherapy beneficial for the treatment of patients with T1bN0M0 triple-negative breast cancer?

Is chemotherapy beneficial for the treatment of patients with T1bN0M0 triple-negative breast cancer?

Posted by on Jan 31, 2021 in Breast cancer | 0 comments

In a nutshell This study evaluated the benefits of chemotherapy after surgery in patients with T1bN0M0 triple-negative breast cancer (TNBC). The data showed that chemotherapy after surgery resulted in similar outcomes as patients who did not undergo chemotherapy. Some background Triple-negative breast cancer (TNBC) is a subtype of breast...

Read More

Intensity-modulated radiation therapy with simultaneously integrated boost leads to shorter treatment time with similar outcomes as conventional radiotherapy after surgery for breast cancer

Intensity-modulated radiation therapy with simultaneously integrated boost leads to shorter treatment time with similar outcomes as conventional radiotherapy after surgery for breast cancer

Posted by on Jan 2, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the effects of intensity-modulated radiation therapy (IMRT) with a simultaneously integrated boost (SIB) to conventional radiotherapy (CRT) with a sequential boost (SeqB) following breast-conserving surgery (BCS) in patients with breast cancer. The data showed that both radiotherapy techniques...

Read More

Pembrolizumab plus chemotherapy can delay progression of advanced triple negative breast cancer

Pembrolizumab plus chemotherapy can delay progression of advanced triple negative breast cancer

Posted by on Dec 31, 2020 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of pembrolizumab (Keytruda) plus chemotherapy in patients with inoperable or metastatic triple-negative breast cancer. The data showed that the combination is effective in improving progression-free survival in these patients. Some background Triple-negative breast cancer (TNBC)...

Read More

Evaluating long-term active surveillance for early-stage prostate cancer.

Evaluating long-term active surveillance for early-stage prostate cancer.

Posted by on Dec 28, 2020 in Prostate cancer | 0 comments

In a nutshell This study was carried out to assess the long-term outcomes of men diagnosed with prostate cancer (PC) undergoing active surveillance (AS) and factors that predicted the risk of their cancer spreading (metastasizing). The authors found that AS is a safe and viable option for men with low-risk and carefully-selected intermediate-risk...

Read More

Chemotherapy improves triple-negative breast cancer survival in older women

Chemotherapy improves triple-negative breast cancer survival in older women

Posted by on Dec 27, 2020 in Breast cancer | 0 comments

In a nutshell This study looked at the outcomes of older women with triple-negative breast cancer who received chemotherapy before or after local treatment. The data showed that chemotherapy can be considered in the treatment of these patients. Some background Triple-negative breast cancer (TNBC) is a subtype of breast cancer (BC) that tests...

Read More

The outcomes of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer

The outcomes of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer

Posted by on Dec 18, 2020 in Lung cancer | 0 comments

In a nutshell The study compared outcomes of lorlatinib (Lorbrena) with crizotinib (Xalkori) in patients with previously untreated advanced non-small-cell lung cancer (NSCLC) with ALK mutations (genetic abnormalities). The main finding was that patients receiving lorlatinib had longer progression-free survival (PFS) and a higher response in the...

Read More

Long term outcomes of accelerated partial breast irradiation with TomoTherapy in invasive breast cancer treated with breast-conserving surgery

Long term outcomes of accelerated partial breast irradiation with TomoTherapy in invasive breast cancer treated with breast-conserving surgery

Posted by on Dec 14, 2020 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate the outcomes of accelerated partial breast irradiation (ABPI) with TomoTherapy (TT) after breast conservative surgery (BCS) in patients with invasive breast cancer.  This study concluded that this treatment is safe and effective with good long-term outcomes in these patients.   Some...

Read More